A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial

Studies suggest that patients with relapsing-remitting multiple sclerosis (RRMS) who do not benefit from other disease-modifying treatments (DMTs) may benefit from converting to glatiramer acetate (GA). COPTIMIZE was a 24-month observational study designed to assess the disease course of patients co...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Neurol
Prif Awduron: Ziemssen, Tjalf, Bajenaru, Ovidiu A., Carrá, Adriana, de Klippel, Nina, de Sá, João C., Edland, Astrid, Frederiksen, Jette L., Heinzlef, Olivier, Karageorgiou, Klimentini E., Lander Delgado, Rafael H., Landtblom, Anne-Marie, Macías Islas, Miguel A., Tubridy, Niall, Gilgun-Sherki, Yossi
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Springer Berlin Heidelberg 2014
Pynciau:
Original Communication
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4221652/
https://ncbi.nlm.nih.gov/pubmed/25119836
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00415-014-7446-0
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg